Editorials

Type of hormone replacement therapy and risk of venous thromboembolism

BMJ 2008; 336 doi: http://dx.doi.org/10.1136/bmj.39556.666944.80 (Published 29 May 2008) Cite this as: BMJ 2008;336:1203
  1. Helen Roberts, senior lecturer in women’s health
  1. 1Department of Obstetrics and Gynaecology, University of Auckland, Auckland 1142, New Zealand
  1. h.roberts{at}auckland.ac.nz

    Transdermal oestrogen may be safer than oral oestrogen

    The results of randomised studies have been fairly consistent in finding an increased risk of venous thromboembolism with oral hormone replacement therapy. The accompanying systematic review by Canonico and colleagues finds similar results.1 The review combined data from both randomised and observational studies and found that the risk of venous thromboembolism doubled with oral hormone replacement therapy compared with placebo (pooled odds ratio 2.4, 95% confidence interval 1.9 to 3.0).

    Results from the observational studies alone were then pooled to assess the risk of venous thromboembolism from different types of hormone replacement therapy and duration of use. No significant difference was seen between combined therapy and oestrogen only (2.6 v 2.2; P=0.45). Risk of venous thromboembolism was significantly higher during the first year of treatment with oral oestrogen (4.0 for a duration of less than one year; 2.1 for more than one year), and past treatment was not associated with an increased risk (1.2, 0.9 to 1.7). The results echo …

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe